CCR6 and myeloid sarcoma: As Tregs have been shown to control Th17 and Th1-mediated tolerance and inflammatory responses in MS and EAE [6], we analyzed total Tregs, as well as Tregs subpopulations that suppress responses mediated by either Th1 (CXCR3+ CCR6-) [9, 10] or Th17 (CXCR3- CCR6+) Tregs [11] lymphocytes.